Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Novo Nordisk's (NVO -0.2%) Victoza's outperformed Merck's (MRK -0.2%) Januvia and Amylin's (BMY)...

  • Tuesday, November 27, 2012, 10:16 AM ET
    Novo Nordisk's (NVO -0.2%) Victoza's outperformed Merck's (MRK -0.2%) Januvia and Amylin's (BMY) exenatid BID in patients with type two diabetes. More subjects given Victoza had a blood-sugar level below 7% those who received the rival drugs. (PR)
Track new comments on this story

This news story has 1 comment:

  •  
    "blood sugar below 7%..." 7% of what? Does this mean the patients using Victoza were hypoglycemic? Blood sugars were 7% lower in patients taking Victorza than the others? That might be good. Blood sugars only lower than the top 7% of those taking the others? Not good. Confusing summary.
    28 Nov 2012, 03:26 PM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »